ISCD Relationships with Industry

The mission of The International Society for Clinical Densitometry (ISCD) is to advance excellence in the assessment of skeletal health by:

- Promoting education and a broader understanding of the clinical applications of bone mass measurement and other skeletal health assessment technologies
- Assuring proficiency and quality in the assessment of skeletal health through certification and accreditation
- Supporting clinical and scientific advances in the diagnosis and treatment of osteoporosis
- Promote appropriate patient access to bone mass measurement and other skeletal health assessment technologies

The ISCD recognizes the important benefits of partnering with industry (for-profit organizations that may have a conflict of interest with the mission of The ISCD) that have led to major medical advances, thereby improving human health. The common interests of healthcare providers and industry to advance medical care makes collaboration valuable. Even so, there are potential risks with any relationship that includes the financial goals of industry, and these may at times conflict with the professional goals of The ISCD (1, 2). It is a principle of the ISCD that collaborating with and accepting financial support from industry does not necessarily reflect a conflict of interest. The ISCD has had in place for some time protective measures as noted below:

1) Educational Programs of the ISCD (CME events)

All CME events will follow ACCME Standards for Commercial Support and other appropriate local regulatory guidelines (3, 4).

2) Position Development Conferences (PDC)

a) Support

In keeping with established ACCME guidelines for accepting commercial support from industry, support from industry for the PDC, if offered and considered appropriate, will be accepted in the form of educational grants for both the program and subsequent publications (3, 4).

b) Participation of Industry in the PDC
Employees of industry who have expertise, not otherwise available, may provide knowledge
crucial to the PDC topics. Employees of industry may suggest, but cannot determine the PDC
topics, content, or the Official Positions generated from the PDC.

3) Non CME Programs

a) Influence on Content

All non-CME programs of The ISCD are independent of all industry influence and as such
industry will have no influence on the content.

b) Commercial Support

In keeping with established guidelines for accepting commercial support from industry,
support for any non-CME program will be accepted in the form of educational grants for both the
program and subsequent publications.

c) Transparency and disclosure

There will be full transparency and disclosure of financial relationships.

4) Disclosure of Board members and ISCD Committee Members Related to Relationships with
Industry.

All members of The ISCD committees and Board members will provide disclosure of any
financial relationships to industry.

5) General budgetary support

Financial support from industry will be accepted for the purpose of supporting the mission of
The ISCD.

6) ISCD Publications

The content of The ISCD publications is free of industry influence. The Journal of Clinical
Densitometry does accept paid advertising from industry.

7) Product endorsements

The ISCD will not endorse any industry products or services for the assessment or treatment
of skeletal health.
REFERENCES


2. Steinbrook R. Controlling Conflicts of Interest- Proposals from the Institute of Medicine; NEJM 2009; 360; 2160-3.


## CONFLICT OF INTEREST INFORMATION FOR THE TASKFORCE PANEL

<table>
<thead>
<tr>
<th>Name</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sanford Baim, MD, CCD</td>
<td>Research: Lilly, Novartis, P&amp;G, Merck, Roche, Amgen</td>
</tr>
</tbody>
</table>
| Neil Binkley, MD, CCD       | Consultant: Merck, Novartis, Lilly  
Speakers’ Bureaus: Novartis, Merck, Roche, P&G, GSK  
Research: Merck, Novartis, Roche, Aventis, GSK,  
Deltanoid, Unigene |
| Catherine Gordon, MD        | Consultant: Gilead Sciences |
| Larry G. Jankowski, CDT     | No Financial Relationships to Disclose |
| Edward S. Leib, MD, CCD     | No Financial Relationships to Disclose |
| Michael Lewiecki, MD, CCD   | Research: Amgen, Eli Lilly, GSK, Novartis, Pfizer, P&G,  
Roche, Sanofi-Aventis, Wyeth  
Consulting: Amgen, Eli Lilly, Novartis, Roche/GSK,  
Upsher-Smith, Wyeth  
Speakers’ Bureaus: Eli Lilly, Novartis, Roche/GSK  
Ownership Interest: General Electric, P&G, Teva |
| Sarah Morgan, MD, RD CCD    | Consulting: Amgen, Roche, Eli Lilly, P&G  
Honoraria for speaking: Novartis, Roche/GSK, Sciele,  
Eli Lilly, P&G  
Research: Roche |
| Christopher R. Shuhart, MD, CCD | Stockholder: Cubist Pharmaceuticals  
Grant Recipient: Hoffman-LaRoche, Inc. |
| S. Bobo Tanner, MD, CCD     | Consulting: Genentech, P&G, Biogen Idec  
Speakers’ Bureaus: Merck, P&G, Sanofi-Aventis,  
Wyeth, Amgen, Novartis, Roche/GSK, Lilly  
Research: Roche, Genentech, Lilly, Wyeth, CSL, Greer |
| Rogene Tesar, PhD, CBDT, CCD| No Financial Relationships to Disclose |
| Nelson Watts, MD, CCD       | Consulting: Amgen, Lilly, Novartis, Novo Nordisk, P&G,  
Sanofi-Aventis  
Honoraria for speaking: Amgen, Novartis, P&G, Sanofi-Aventis  
Research: Amgen, Lilly, Merck, Novartis, P&G, Sanofi-Aventis |